{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:06:20Z","timestamp":1794431180227,"version":"4.9.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eosinophils are key factors to the pathogenesis of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). Monoclonal antibodies targeting the interleukin-5 (IL-5) pathway (mepolizumab and benralizumab) often lead to rapid symptom control and enable tapering of oral corticosteroids (OCS) in many patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present the case of a 51-year-old male patient with severe eosinophilic asthma, peripheral blood eosinophilia, and ear, nose, and throat (ENT) involvement, treated with benralizumab (30\u00a0mg every 8\u00a0weeks) and oral corticosteroids. During tapering of corticosteroids, the patient developed diffuse alveolar haemorrhage as a manifestation of overt vasculitis. Subsequently, elevated troponin T levels were detected, and further diagnostic work-up revealed both myocardial involvement consistent with EGPA and an acute myocardial infarction due to occlusion of the left anterior descending (LAD) artery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Central immunopathogenic pathways involved in vasculitis are not targeted by IL-5 antibodies and vasculitic manifestations may relapse or even newly emerge despite ongoing biological therapy. Elevated troponin levels in EGPA patients should only be attributed to EGPA once other potential causes of myocardial injury are ruled out.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04106-4","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:34:08Z","timestamp":1768008848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unmasking EGPA with near fatal diffuse alveolar haemorrhage in severe eosinophilic asthma under treatment with benralizumab: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Nora","family":"Drick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till Frederik","family":"Kaireit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Ruwisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schallhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Seeliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"4106_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221794","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221794.","journal-title":"Ann Rheum Dis"},{"key":"4106_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/BOR.0000000000000015","volume":"26","author":"A Mahr","year":"2014","unstructured":"Mahr A, Moosig F, Neumann T, et al. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol. 2014;26:16\u201323. https:\/\/doi.org\/10.1097\/BOR.0000000000000015.","journal-title":"Curr Opin Rheumatol"},{"key":"4106_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi G, Bettiol A, Gelain E, et al. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19:378\u201393. https:\/\/doi.org\/10.1038\/s41584-023-00958-w.","journal-title":"Nat Rev Rheumatol"},{"key":"4106_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1803537.","journal-title":"N Engl J Med"},{"key":"4106_CR5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024;390:911\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2311155.","journal-title":"N Engl J Med"},{"key":"4106_CR6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard-2023-224624","volume":"82","author":"A Cottu","year":"2023","unstructured":"Cottu A, Groh M, Desaintjean C, et al. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2023;82:1580\u20136. https:\/\/doi.org\/10.1136\/ard-2023-224624.","journal-title":"Ann Rheum Dis"},{"key":"4106_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.01.006","author":"AM Nanzer","year":"2024","unstructured":"Nanzer AM, Maynard-Paquette A-C, Alam V, et al. Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2024. https:\/\/doi.org\/10.1016\/j.jaip.2024.01.006.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4106_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-015-0138-4","volume":"16","author":"N Tsurikisawa","year":"2015","unstructured":"Tsurikisawa N, Oshikata C, Tsuburai T, et al. Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis. BMC Immunol. 2015;16:75. https:\/\/doi.org\/10.1186\/s12865-015-0138-4.","journal-title":"BMC Immunol"},{"key":"4106_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906\u201315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.872903.","journal-title":"Circulation"},{"key":"4106_CR10","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.ard.2025.06.2131","volume":"84","author":"PA Merkel","year":"2025","unstructured":"Merkel PA, Nair PK, Khalidi N, et al. Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2025;84:1888\u201399. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2131.","journal-title":"Ann Rheum Dis"},{"key":"4106_CR11","doi-asserted-by":"publisher","unstructured":"Puan Y, Ong KY, Tiew PY, et al. Characteristics of Severe Asthma Clinic Patients With Eosinophilic Granulomatosis With Polyangiitis. The Journal of Allergy and Clinical Immunology: In Practice. 2025;13:361-368.e2. https:\/\/doi.org\/10.1016\/j.jaip.2024.10.013","DOI":"10.1016\/j.jaip.2024.10.013"},{"key":"4106_CR12","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00296-021-04950-z","volume":"42","author":"T Mutoh","year":"2021","unstructured":"Mutoh T, Shirai T, Sato H, et al. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review. Rheumatol Int. 2021;42:2069\u201376. https:\/\/doi.org\/10.1007\/s00296-021-04950-z.","journal-title":"Rheumatol Int"},{"key":"4106_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.lpm.2013.02.308","volume":"42","author":"JF Cordier","year":"2013","unstructured":"Cordier JF, Cottin V, Guillevin L, et al. L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). La Presse M\u00e9dicale. 2013;42:507\u201310. https:\/\/doi.org\/10.1016\/j.lpm.2013.02.308.","journal-title":"La Presse M\u00e9dicale."},{"key":"4106_CR14","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1093\/rheumatology\/keab027","volume":"60","author":"E Garcia-Vives","year":"2021","unstructured":"Garcia-Vives E, Rodriguez-Palomares JF, Harty L, et al. Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal. Rheumatology. 2021;60:4538\u201347. https:\/\/doi.org\/10.1093\/rheumatology\/keab027.","journal-title":"Rheumatology"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04106-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:23:33Z","timestamp":1769585013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04106-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4106"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04106-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval from an institutional review board was not required, as this is a single case report with all patient identifiers removed from the text and images. A clinical trial registration number is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Nora Drick has received lecturing and consulting fees Glaxo-Smith-Klein, Sanofi and AstraZeneca.Till Kaireit has received lecturing fees from Siemens Healthineers, all unrelated to the present work.Jannik Ruwisch: has received lecturing and consulting fees from Boehringer Ingelheim and AstraZeneca.Sven Schallhorn has nothing to declare.Johann Bauersachs received honoraria for lectures\/consulting from Novartis, Abbott, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Edwards, Roche, Zoll not related to this article; and research support for the department from Zoll, CVRx, Abiomed, Norgine, Roche, all unrelated to the present work.Heiko Schenk has received fees for lectures or consultations from AstraZeneca, Glaxo-Smith-Kline, and Otsuka, all unrelated to the present work.Marius M. Hoeper has received fees for lectures or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GossamerBio, Janssen, Keros, and MSD, all unrelated to the present work.Torsten Witte has received lecturing and consulting fees from Glaxo-Smith-Kline and from AstraZeneca.Benjamin Seeliger has received lecturing and consulting fees from Boehringer Ingelheim, Glaxo-Smith-Klein and AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}